News
After issues with a batch of Jasper Therapeutics' investigational antibody led to "lower" therapeutic effects in several ...
A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s ...
The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...
After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...
Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results